Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
Go back to Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease| Johnson & Johnson (NYSE: JNJ) | Delayed: 238.33 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $238.33 | 52 Week High | $126.07 | |||
| Open | $238.33 | 52 Week Low | $94.28 | |||
| Day High | $238.33 | P/E | 49.55 | |||
| Day Low | $238.33 | EPS | $4.81 | |||
| Volume | 2,354 | |||||
